Drug Trial Radar · NCT05881811
The Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Mar 20, 2023
Primary completion
Apr 24, 2023
Study completion Jun 5, 2023
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, crossover study, conducted in healthy Chinese populations, and plans to enroll 48 healthy adult subjects (male and female).
Conditions
- PHN - Post-Herpetic Neuritis
Interventions
HSK16149,probenecid, cimetidineDrug
40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: From the start to 72 hours after administration
- AUC0-tTime frame: From the start to 72 hours after administration
- AUC0-infTime frame: From the start to 72 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Jishuitan Hoispital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.